AstraZeneca COVID-19 Vaccine Trial Volunteer Showed Symptoms Of Rare Neurological Disorder
reported. ” data-reactid=”19″>AstraZeneca Plc (NYSE: AZN) CEO Pascal Soriot said during a conference call with investors Wednesday that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause, Stat reported.
The diagnosis wasn’t confirmed and the woman could to be discharged from the hospital as soon as Wednesday, according to the executive.
A board overseeing safety and data components of the trial reportedly confirmed that the participant was injected with the British drugmaker’s COVID-19 vaccine and not a placebo.
Additionally, Soriot said that the vaccine trial was also halted earlier in July after a person suffered neurological symptoms, diagnosed as multiple sclerosis. The event was unrelated to the effects of vaccine, according to AstraZeneca.
temporarily halted its vaccine trial to allow an independent committee to conduct a safety review. ” data-reactid=”28″>Why It Matters: On Tuesday, the drugmaker temporarily halted its vaccine trial to allow an independent committee to conduct a safety review.
not the first instance of the trial being stopped, as per Sky News.” data-reactid=”29″>United Kingdom Health Minister Matt Hancock called the halt a “standard process” when something new needs to be investigated and confirmed that this was not the first instance of the trial being stopped, as per Sky News.
MRNA) shares closed nearly 5% higher on Wednesday on the news of AstraZeneca’s trial woes.
Moderna confirmed to SVB Leerink analyst Mani Foroohar that it expects no impact from AstraZeneca-Oxford adverse event on its coronavirus efficacy study.
PFE) are likely to be distributed early on in the United States to health care workers and high-risk groups, according to the New York Times.
View Article Origin Here